The US Chronic Pain Market – Focus on Opioids: Trends & Opportunities (2014-19) November 2014
The US Chronic Pain Market – Focus on Opioids Scope of the report The report titled “The US Chronic Pain Market – Focus on Opioids: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and Nektar Theropeutics are profiled.
Segment Coverage o Oxycodone o Hydrocodone o Morphine o Hydromorphone o Fentanyl o Dihydrocodeine o Methadone
The US Chronic Pain Market – Focus on Opioids Executive Summary Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating. The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.
The US Chronic Pain Market – Focus on Opioids About 100 million Americans suffer from chronic pain, defined as pain that lasts longer than six months. Chronic pain can be mild or excruciating, episodic or continuous, merely inconvenient or totally incapacitating. Chronic pain treatment depends on the individual patients, their diagnosis and their pain severity.
US Chronic Pain Market 2009-2013E
US Chronic Pain Market 2014F-19F (in US$ billions)
(in US$ billions)
2009
2010
2011
2012
2013E
• Market size of the US Chronic Pain Therapy is expected to reach to US$…… billions in the year 2019, from US$…… billions in 2014 by growing at a CAGR of………%. • Growth in the market is due to …………………………………………….
The US Chronic Pain Market – Focus on Opioids US Oxycodone Market: by value- 2009-2013E (in US$ billion)
2009
2010
2011
2012
2013E
US Methadone Market: by value- 2014-19F (in US$ million)
US Methadone Market: by value- 2009-13E (in US$ million)
2009
2010
2011
2012
US Oxycodone Market: by value- 2014-19F (in US$ billion)
2013E
The US Chronic Pain Market – Focus on Opioids US Morphine Market: by value- 2009-13E (in US$ million)
2009
2010
2011
2012
2013E
US Hydromorphone Market: by value- 2014F-2018F
US Morphine Market: by value- 2014F-2019F (in US$ million)
2014F
2015F
2016F
2017F
2018F
2019F
US Dihydrocodeine Market: by value- 2014F-18F (in US$ billion)
(in US$ million)
Chart Title
2014E
2015E
2016E
2017E
2018E
2014E
2015E
2016E
2017E
2018E
3.2 Opioid Sales in US Chronic Pain Market - Forecast: Sizing & Growth
Table of Contents
4. The US Chronic Pain Therapy Market: Segment Analysis 4.1 The US Oxycodone Market: Size and Growth 4.2 The US Methadone Market: Size and Growth 4.3 The US Morphine Market: Size and Growth 4.4 The US Hydromorphone Market: Size and Growth 4.5 The US Hydrocodone Market: Size and Growth 4.6 The US Dihydrocodeine Market: Size and Growth 4.7 The US Fentanyl Market: Size and Growth 5. The US Chronic Pain Therapy: Market Share Analysis 6. Growth Drivers and Challenges
6.1 Growth Drivers 6.1.1 Rising Healthcare Expenditures 6.1.2 Rise in Aging Demographics 6.1.3 Economic Development 6.2 Market Challenges
List of Figures and Tables
Table 1: Types of Acute and Chronic pain Table 2: WHO Guidelines for Pain Therapy Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions) Figure 2: US Opioid Sales in Chronic Pain Therapy Market - Forecast: 2014F-2019F (US$ B) Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion) Figure 4: Oxycodone Market: Share of Leading Players Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion) Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million) Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 8: US Morphine Market: by value- 2009-13 (in US$ million) Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 10: US Long- Acting Morphine Market: 2014 Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million) Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million) Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion) Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion) Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion) Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion) Figure 17: US Fentanyl Market: by value- 2009-13 (in US$ million) Figure 18: US Fentanyl Market: By value – Forecast: - 2014F-19F (in US$ million)
Figure 19: The US Chronic Pain Therapy Market: Share of Opioids, 2013 Figure 20: US Healthcare Expenditures per Capita, 2007-2013E (in US$) Figure 21: Growth of the US Aging population, 60 years and above as a percentage of total population, 2007-13E (in%) Figure 22: US GDP, 2007-13E (in Current US$ trillions) Figure 23: Number of Drugs Approval by FDA, 2000-2009 Figure 24: Incidence of Pain in the US (in%) Table 3: Leading Players of US Chronic Pain Therapy Market Table 4: US Chronic Pain Therapy Market: Key Players and their product areas Figure 25: Percentage share of Long Acting Morphine – Value (in %) Table 5: Long Acting Morphine: Competition and Market Share Table 6: US Chronic Pain Therapy Market: Sales of Leading Companies Figure 26: Zogenix Inc. Product Revenue, FY 2011-13 (in US$ million) Figure 27: Zogenix Inc. R&D Expenditure, FY 2011-13 ($ m) Table 7: Products offered by Egalet
Title: The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019) Published: November 2014 Pages: 68 Price: US$ 800 (Single-User License) : US$ 1600 (Corporate License) For placing an order of the Report, please press the following link:
http://www.daedal-research.com//the-us-chronic-pain-market-focus-on-opioids-trends-opportunities-2014-2019
For more details please contact Mr. Rajeev Kumar: Tel: +91-120-4553017 (9.30 am - 6.30 pm) IST Mobile: +91-8743975789 (24 X7) Enquiries: info@daedal-research.com
Daedal Research
Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. The research firm offers a blend of the best strategic consulting and market research solutions, which promise data rich, cost effective, and highly insightful analysis to help its clients with perfect answers to their important business queries .